FIELD

(redirected from Fenofibrate Intervention and Event Lowering in Diabetes)
AcronymDefinition
FIELDFoundation for International Environmental Law and Development (UK)
FIELDFoundation for International Environmental Law and Development
FIELDFund for Innovation, Effectiveness, Learning and Dissemination (Washington, DC)
FIELDFenofibrate Intervention and Event Lowering in Diabetes (heart medication trial)
FIELDFinancial Information Engine on Land Degradation
FIELDFriendly Integrated Environment for Learning and Development
References in periodicals archive ?
Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, et al; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators.
32) Results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study showed that lowering cholesterol in patients with T2DM using fenofibrate slowed the progression of albuminuria over 5 years of follow-up.
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was designed to assess whether long-term lipid-lowering therapy with fenofibrate could reduce adverse macrovascular and microvascular outcomes.
FIELD, the Fenofibrate Intervention and Event Lowering in Diabetes study, evaluated the effect of fenofibrate 200 mg/d among 9795 type 2 diabetic patients who were not taking a statin.
The new retinopathy findings came from a prespecified, tertiary analysis in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which involved 9,795 patients with type 2 diabetes at 63 centers in Australia, New Zealand, and Finland.
The new retinopathy findings came from a prespecifed, tertiary analysis in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which involved 9,795 patients with type 2 diabetes at 63 centers in Australia, New Zealand, and Finland.
DALLAS -- Expectations were high for a big positive result in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, the largest-ever randomized prospective trial of cardiovascular intervention in type 2 diabetes.